Luteinizing hormone receptor status and clinical, pathologic, and prognostic features in patients with breast carcinomas

Cancer

Volumn 97, Issue 7, 2003, Pages 1810-1816

  Meduri, Geri ^a   Charnaux, Nathalie ^a   Spyratos, Frederique ^b   Hacene, Kamel ^b   Loosfelt, Hugue ^a   Milgrom, Edwin ^a  

^a BICÊTRE HOSPITAL   (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

Breast carcinoma; Human chorionic gonadotropin (hCG); Luteinizing hormone receptor (LHR); Lutenizing hormone

Indexed keywords

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN RECEPTOR; ESTROGEN RECEPTOR; LUTEINIZING HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER INFILTRATION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL; CELL DIFFERENTIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, LH; TREATMENT OUTCOME;

EID: 0037378475     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11294     Document Type: Article

References (27)

1. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Reu. 1993;15:36-47.
2. Russo J, Wilgus G, Russo IH. Susceptibility of the mammary gland to carcinogenesis. I. Differentiation of the mammary gland as determinant of tumor incidence and type of lesion. Am J Pathol. 1979;96:721-734.
3. Russo IH, Koszalka M, Russo J. Human chorionic gonadotropin and rat mammary cancer prevention. J Natl Cancer Inst. 1990;82:1286-1289.
4. Russo J, Russo IH. Hormonally induced differentiation: a novel approach to breast cancer prevention. J Cell Biochem. 1995;22:58-64.
5. Russo TH, Koszalka M, Gimotty PA, Russo J. Protective effect of chorionic gonadotropin on DMBA-induced mammary carcinogenesis. Br J Cancer. 1990;62:243-247.
6. Srivastava P, Russo J, Russo IH. Chorionic gonadotropin inhibits rat mammary carcinogenesis through activation of programmed cell death. Carcinogenesis. 1997;18:1799-1808.
7. You S, Tu ZJ, Kiang DT. Direct modulation of tumor suppressor connexin 26 gene by human chorionic gonadotropin in rat mammary gland. Cancer Res. 1998;58:1498-1502.
8. Hirschi KK, Xu CE, Tsukamoto T, Sager R. Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Diff. 1996;7:861-870.
9. Baserga R. The insulin-growth factor I receptor: a key to tumor growth? Cancer Res. 1995;55:249-252.
10. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472-1489.
11. Sachdev D, Yee D. The IGF system and breast cancer. Endocrine Relat Cancer. 2001;8:197-209.
12. Huynh H. In vivo regulation of the insulin-like growth factor system of mitogens by human chorionic gonadotropin. Int J Oncol. 1998;13:571-575.
13. Lojun S, Bao S, Lei ZM, Rao CV. Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against breast cancer. Biol Reprod. 1997;57:1202-1210.
14. Meduri G, Charnaux N, Loosfelt E, et al. Luteinizing hormone/choriogonadotropin receptors in breast cancer. Cancer Res. 1997;57:857-864.
15. Russo IH, Russo J. Hormonal approach to breast cancer prevention. J Cell Biochem. 2000;77:1-6.
16. Rao CV. Does full-term pregnancy at a young age protect women against breast cancer through hCG? Obstet Gynecol. 2000;96:783-786.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Peto R, Pike MC. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
19. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariable analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989; 64:1914-1921.
20. Russo J, Russo IH. Toward a physiologic approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prevent. 1994;3:353-364.
21. Hansen RK, Bissell MJ. Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones. Endocrine Relat Cancer. 2000;7:95-113.
22. Pichon MF, Broet P, Magdelenat H, et al. Prognostic value of steroid receptor after long-term follow-up of 2257 operable breast cancers. Br J Cancer. 1997;73:1545-1551.
23. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer. 2001;37:347-354.
24. Bieche I, Lazar V, Nogues C, et al. Prognostic value of chorionic gonadotropin β gene transcripts in human breast carcinoma. Clin Cancer Res. 1998;4:671-676.
25. Bieche I, Parfait B, Le Doussal V, et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res. 2001;61:1652-1658.
26. Babu PS, Krishnamurthy H, Chedrese PJ, Sairam MR. Activation of extracellular-regulated kinase pathways in ovarian granulosa cells by the novel growth factor type follicle-stimulating hormone receptor. J Biol Chem. 2000;275:27615-27626.
27. Lapthorn AJ, Harris DC, Littlejohn A, et al. Crystal structure of human chorionic gonadotropin. Nature. 1994;369:455-461.